Article: Transplantation in 2011: New agents, new ideas and new hope

The past year was marked by several excellent studies that represent important therapeutic advances in kidney transplantation or that further our understanding of the genetic basis of chronic allograft dysfunction, clinical tolerance and outcomes of kidney transplantation.

Citing Articles

MiR-146a regulates regulatory T cells to suppress heart transplant rejection in mice.

Lu J, Wang W, Li P, Wang X, Gao C, Zhang B Cell Death Discov. 2021; 7(1):165.

PMID: 34226512 PMC: 8257678. DOI: 10.1038/s41420-021-00534-9.

Malignancies in a renal transplant population: The St. Michael's Hospital experience.

Saleeb R, Faragalla H, Yousef G, Stewart R, Streutker C Urol Ann. 2016; 8(2):163-7.

PMID: 27141185 PMC: 4839232. DOI: 10.4103/0974-7796.165712.

IL-34 is a Treg-specific cytokine and mediates transplant tolerance.

Bezie S, Picarda E, Ossart J, Tesson L, Usal C, Renaudin K J Clin Invest. 2015; 125(10):3952-64.

PMID: 26389674 PMC: 4607123. DOI: 10.1172/JCI81227.

Differing effects of rapamycin or calcineurin inhibitor on T-regulatory cells in pediatric liver and kidney transplant recipients.

Akimova T, Kamath B, Goebel J, Meyers K, Rand E, Hawkins A Am J Transplant. 2012; 12(12):3449-61.

PMID: 22994804 PMC: 3513508. DOI: 10.1111/j.1600-6143.2012.04269.x.

References

1.

Newell K, Asare A, Kirk A, Gisler T, Bourcier K, Suthanthiran M . Identification of a B cell signature associated with renal transplant tolerance in humans. J Clin Invest. 2010; 120(6):1836-47. PMC: 2877933. DOI: 10.1172/JCI39933. View

2.

Montgomery R, Lonze B, King K, Kraus E, Kucirka L, Locke J . Desensitization in HLA-incompatible kidney recipients and survival. N Engl J Med. 2011; 365(4):318-26. DOI: 10.1056/NEJMoa1012376. View

3.

Merion R, Ashby V, Wolfe R, Distant D, Hulbert-Shearon T, Metzger R . Deceased-donor characteristics and the survival benefit of kidney transplantation. JAMA. 2005; 294(21):2726-33. DOI: 10.1001/jama.294.21.2726. View

4.

Friedman D, Kozlitina J, Genovese G, Jog P, Pollak M . Population-based risk assessment of APOL1 on renal disease. J Am Soc Nephrol. 2011; 22(11):2098-105. PMC: 3231785. DOI: 10.1681/ASN.2011050519. View

5.

Reeves-Daniel A, DePalma J, Bleyer A, Rocco M, Murea M, Adams P . The APOL1 gene and allograft survival after kidney transplantation. Am J Transplant. 2011; 11(5):1025-30. PMC: 3083491. DOI: 10.1111/j.1600-6143.2011.03513.x. View

6.

Lozano J, Pallier A, Martinez-Llordella M, Danger R, Lopez M, Giral M . Comparison of transcriptional and blood cell-phenotypic markers between operationally tolerant liver and kidney recipients. Am J Transplant. 2011; 11(9):1916-26. DOI: 10.1111/j.1600-6143.2011.03638.x. View

7.

Vincenti F, Charpentier B, Vanrenterghem Y, Rostaing L, Bresnahan B, Darji P . A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant. 2010; 10(3):535-46. DOI: 10.1111/j.1600-6143.2009.03005.x. View

8.

Kayler L, Srinivas T, Schold J . Influence of CIT-induced DGF on kidney transplant outcomes. Am J Transplant. 2011; 11(12):2657-64. DOI: 10.1111/j.1600-6143.2011.03817.x. View

9.

Larsen C, Pearson T, Adams A, Tso P, Shirasugi N, Strobert E . Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am J Transplant. 2005; 5(3):443-53. DOI: 10.1111/j.1600-6143.2005.00749.x. View

10.

Vincenti F, Larsen C, Alberu J, Bresnahan B, Garcia V, Kothari J . Three-year outcomes from BENEFIT, a randomized, active-controlled, parallel-group study in adult kidney transplant recipients. Am J Transplant. 2011; 12(1):210-7. DOI: 10.1111/j.1600-6143.2011.03785.x. View

Transplantation in 2011: New Agents, New Ideas and New Hope